15 Mr. Alberto Diaz+++

7/31/2019 15 Mr. Alberto Diaz+++

1/33

Biotechnology

Industrial Biotechnology in Argentina:Enterprises and Potentialities

Alberto Daz

DirectorIndustrial Biotechnology Center INTI

Dias tecnolgicos Argentina Repblica Checa 2009 Nov., 25


2/33

Industrial Biotechnology Center


3/33


BIOTECHNOLOGY PUBLIC SECTOR in Argentina

Tradition (school) in biomedicine, specially.

Nowadays: seeds and agrifoods.

Human Resources: education in biologicalsciences.


4/33

Industrial Biotechnology Center Biotechnology in Argentina. State actions:

Establishment of the Ministry for Science, Technology andProductive Innovation: 2007.

Law to Promote Modern Biotechnology: now being regulated.

Tenders to set up sectorial funds: health care, energy, agro-industries and social development.

Programmes to set up technology based enterprises; training ofhuman resources; sectorial funds for new technologies.

Importance of R&D in biomedicine. Agro foods.


5/33

Industrial Biotechnology Center PUBLIC SECTOR

PERSONNEL YEAR 2008Researchers: 5.661Scholarship holders: 6.598Technicians: 2.291

Total: 14.550 (Year 2003: 8.602)

Biologic and Health Care SciencesResearchers: 1.844Scholarship holders: 2.149I

Technicians: 710

Total: 4.703 (approx. 30 %)


6/33


6.640 (45 % int. coop.).60004000

200720061998

Argentina. S.C.I. Publications

2007:Life Sciences: 2.281Clinical Medicine: 1604


7/33

Economic impacts of biotechnology

on the Argentinean economyPICT. 2002 Cdigo de proyecto 02-13063


8/33

OUTLINE OF ARGENTINE BIOTECHNOLOGICAL

PRIVATE FIRMS

100.00100.0084TOTAL

23.8111.3020Human Health

11.9015.3710Food Ingredients for Bioprocessing

11.9024.7810Animal Health

22.6241.0519Seeds and Plantines

29.777.5125InoculantsAgriculture and

livestock

Firms/Total FirmsParticipation

in biotechsales

Number ofFirms

Industry

Source: a)Extracted from the "Economic Impacts of Biotechnology on Agriculture, Food and

Health Industries in Argentina", Project PICT 2002 -2004 Code 02-13063 Database.b) Biotechnology and Development. A pattern to set up in Argentina Ed. Prometeo yUNGS - December 2006 .

- Quantity and percentage -



9/33

INVESTMENT IN INNOVATION (R&D)

SELECTED PRIVATE BIOTECHNOLOGICALFIRMS ARGENTINA 2002/03-thousand pesos and percentages-

5.270.950,027950,1605,560,968TOTAL

15.555.216,696107,383321,175Human Health

1.450.892,112146,030237,140Food Ingredients

2.751.726,478235,425377,500

Animal

Health

5.940.5223,181390,0004,462,523Seeds2.190.961,56071,322162,630Vaccines

Agriculture

and

Livestock

Biological &

Biotechnologi

cal Sales

Total Sales

Biological &

Biotechnolo

gical

Total

Investment in R&D/

Investment

in R&D

Sales

Area

Note: * 71 firms were selected from the poll.

Source: Extracted from the "Economic Impacts of Biotechnology on Agriculture, Food and Health

Industries in Argentina", Project PICT 2002 - Code 02-13063 database.


10/33


11/33

Quilmes Natl Univ UNQUniv Buenos Aires UBA

Nat Acad Medicine

Natl Res Council CONICET

Garrahan Children Hosp

Roffo Oncology Inst

R+D in CancerStrategic ProgramConsortium of Public Institutions and Companies

ROMIKIN SA

ELEA SACIFyA

International Partners: Center of Molecular Immunology and Center

of Genetic Engineering and Biotecnology (Cuba); Europharma

(Brazil); Kalbe Biotech (Indonesia); Chemo France (France).


12/33

VEGF Vaccine(Solid tumors)

Products PreclinicalPhase

IPhase

IIPhase

III

Racotumomab vaccine(Lung cancer)

NGcGM3 Molecular vaccine(Breast cancer; melanoma)

VSSP Immunological adyuvant(HIV-Aids; cancer)

Anti-CK2 Proapoptotic peptide(Condiloma genital y Cncer crvicouterino)

Vasopressin Peptide analogs(Breast cancer surgery)

Anti-RhoGTPases Small compounds(Prostate and breast cancer; glioma)

Pipeline and development phases

Done

In course

To bestarted


13/33

Argentina: Evolucin de la superficie cultivada con OGM

0%

20%

40%

60%

80%

100%

96/97 97/98 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07

Maz Algodn Soja

Fuente: ArgenBio, 2007


14/33

Argentina: evolucin de la superficie total con OGM(en millones de hectreas)

Fuente: ArgenBio, 2007

0,0

4,0

8,0

12,0

16,0

20,0

96/97

97/98

98/99

99/00

00/01

01/02

02/03

03/04

04/05

05/06

06/07

18,4


15/33

PROVEEDORES

DE TECNOLOG A

9%

PRODUCTORES76%

SEMILLA

4%

GLIFOSATO

5%

ESTADO

NACIONAL

15%

Beneficio Total Acumulado: 19.737,06 millones de dlares

Distribucin de los beneficios generados por laadopcin de la soja GM (1996-2005):

E. Trigo, E. Cap, 2007


16/33

LA RE-INVENCIN DE BIOCERES 2007

Un grupo de empresas que abarca toda la Cadena de Valor de la

Biotecnologa

.Desde el Campo al Laboratorio y desde el Laboratorio al

Campo.

BIOCERES S.A. se convierte en un Holding (Grupo)


17/33

GRUPO BIOCERES


18/33

BIOGNESIS - BAG Anual production capacity

Food Mouth Disease (FMD): 200 M doses

Bovine Vaccines: 100 M doses. Rage vaccine: 20 M doses


19/33

Conclusions A set of local private firms began to develop biotech products

and technology at 80.

In general are SME, financed with local capital.

Nowadays, approximately 70 private companies workingdeveloping biotech.

1996: first GMO approved.

There are in Argentine a relevant critical mass of firms withcapacities of further develop process, new products, joint

ventures and internationalization. There are a tradition (school) and relevant critical mass of

researchers in biomedicine with high capacity to development.



20/33


21/33


22/33

CENTRO DE BIOTECNOLOGIA INDUSTRIAL DEL INTI.Primera Etapa

Dominar tecnologa bsica molecular y procesos


23/33


24/33

Centro de biotecnologia industrial INTI

Edificio 51: En los 51 aos de INTIDe la biologia molecular a la Biotecnologa

De la biotecnologa a la BioIndustria


25/33


26/33



27/33

Industrial Biotechnology Center Las Abuelas (Grandmothers) and Genetics: the

contribution of science to the identification of the childrenof the desaparecidos.

An example of the successful result of biotechnology, with animportant ethical and social repercussion.

It shows that social demands also produce innovation and usefulresults.

It pressed scientists to provide urgent responses. It may become an example for enterprises to carry out R&D:

knowledge; time; adequate funding.

INTERNATIONAL COOPERATION WAS NECESSARY


28/33

Thank you


29/33


30/33

Cooperacin Comunidad Europea - MERCOSUR


31/33

Empresas Biotecnolgicas en Argentinaseleccionadas 2002/2003

10085Totales

11,3020Salud Humana

15,3710IngredientesAlimentos

24,7810Sanidad Animal

41,0520Semillas/Plantines7,5125Inoculantes

% Ventas BiotecTotal (N)Sector


32/33

Biotechnology companies in Argentina2002/2003

10085Total

11.3020Human Health

15.3710Food

ingredients

24.7810Animal Health

41.0520Seeds/Micropr.

7.5125Inoculants

% Sale Biotech.Total (N)Sector


33/33

Documents

15 Mr. Alberto Diaz+++